

# Giovanna Gallo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9500885/publications.pdf>

Version: 2024-02-01

59  
papers

664  
citations

686830

13  
h-index

713013

21  
g-index

61  
all docs

61  
docs citations

61  
times ranked

660  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Natriuretic Peptides for Hypertension Treatment. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 15-21.	1.0	10
2	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 91-102.	1.0	17
3	Hypertension and COVID-19: Current Evidence and Perspectives. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 115-123.	1.0	44
4	Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy. Heart, 2022, 108, 1629-1636.	1.2	6
5	Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set. European Journal of Preventive Cardiology, 2022, 29, 1680-1688.	0.8	11
6	Impact of a NDUF2 Variant on the Occurrence of Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	3
7	Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. Cardiovascular Research, 2021, 117, 1992-1994.	1.8	5
8	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. International Journal of Cardiology, 2021, 327, 138-145.	0.8	19
9	Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. Journal of Human Hypertension, 2021, , .	1.0	7
10	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 255-262.	1.0	1
11	Insights from Cardiopulmonary Exercise Testing in Pediatric Patients with Hypertrophic Cardiomyopathy. Biomolecules, 2021, 11, 376.	1.8	3
12	A Plea for Smoking-Free Policies in COVID-19 Times: Cardiovascular Prevention as an Ally in Coronavirus Containment. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 325-326.	1.0	0
13	Cardiopulmonary exercise testing: An increasingly important step in managing hypertrophic cardiomyopathy.. International Journal of Cardiology, 2021, 332, 138-139.	0.8	3
14	A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. Frontiers in Physiology, 2021, 12, 643721.	1.3	8
15	Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?. European Heart Journal, 2021, 42, 3753-3755.	1.0	9
16	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. Frontiers in Physiology, 2021, 12, 652163.	1.3	14
17	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. Cardiology, 2021, , .	0.6	2
18	Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 541-545.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Relationship Between Cardiorespiratory Fitness, Baseline Blood Pressure and Hypertensive Response to Exercise in the Ferrari Corporate Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 29, 81.	1.0	12
20	Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach. <i>Hypertension</i> , 2021, 78, 1868-1870.	1.3	9
21	Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. <i>Frontiers in Medicine</i> , 2021, 8, 798958.	1.2	88
22	New approach to blood pressure control: Triple combination pill. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 72-77.	2.3	13
23	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 368-377.	1.4	23
24	Atrial fibrillation and ischaemic heart disease: should we use acetylsalicylic acid beside anticoagulants?. <i>European Heart Journal Supplements</i> , 2020, 22, L166-L169.	0.0	4
25	Markers of Cardiotoxicity in Early Breast Cancer Patients Treated With a Hypofractionated Schedule: A Prospective Study. <i>Clinical Breast Cancer</i> , 2020, 21, e141-e149.	1.1	7
26	Natriuretic Peptides, Cognitive Impairment and Dementia: An Intriguing Pathogenic Link with Implications in Hypertension. <i>Journal of Clinical Medicine</i> , 2020, 9, 2265.	1.0	7
27	Systolic blood pressure target less than 120 mmHg: the "Chariot Allegory"™ in hypertension?. <i>Journal of Hypertension</i> , 2020, 38, 1462-1463.	0.3	2
28	COVID-19 and the Forgotten Majority. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 339-339.	1.0	6
29	Sacubitril/Valsartan: Potential Impact of ARNi "Beyond the Wall" of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 616564.	1.1	4
30	Risk stratification in heart failure with mild reduced ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 59-64.	0.8	9
31	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. <i>Journal of Clinical Medicine</i> , 2020, 9, 1636.	1.0	15
32	Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1348.	1.0	7
33	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. <i>International Journal of Cardiology</i> , 2020, 316, 172-179.	0.8	15
34	To whom recommend intensive treatment for hypertension?. <i>European Heart Journal Supplements</i> , 2020, 22, E167-E172.	0.0	3
35	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , 2020, 26, 932-943.	0.7	8
36	Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension. <i>Current Hypertension Reports</i> , 2019, 21, 85.	1.5	9

#	ARTICLE	IF	CITATIONS
37	Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: Room for monotherapy?. <i>International Journal of Cardiology</i> , 2019, 291, 105-111.	0.8	3
38	Molecular and clinical implications of natriuretic peptides in aortic valve stenosis. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 129, 266-271.	0.9	11
39	Implications of Guidelines for Hypertension Management in Europe. <i>Circulation Research</i> , 2019, 124, 972-974.	2.0	14
40	The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2019, 286, 127-133.	0.8	19
41	Aspirin in primary prevention. <i>Journal of Hypertension</i> , 2019, 37, 2298-2299.	0.3	1
42	Highlights of ESC/ESH 2018 Guidelines on the Management of Hypertension: What Every Doctor Should Know. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 1-8.	1.0	22
43	The "hidden side of the moon" in hypertension: When and why is dangerous low diastolic blood pressure?. <i>International Journal of Cardiology</i> , 2019, 276, 268-270.	0.8	2
44	Is early and fast blood pressure control important in hypertension management?. <i>International Journal of Cardiology</i> , 2018, 254, 328-332.	0.8	56
45	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 327-341.	1.0	18
46	Role of oxidative stress in the process of vascular remodeling following coronary revascularization. <i>International Journal of Cardiology</i> , 2018, 268, 27-33.	0.8	30
47	Chronic heart failure is characterized by altered mitochondrial function and structure in circulating leucocytes. <i>Oncotarget</i> , 2018, 9, 35028-35040.	0.8	15
48	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 313-329.	1.0	9
49	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 331-339.	1.0	8
50	Recurrence of acute coronary syndrome during inadequate control of cardiovascular risk factors. <i>Atherosclerosis</i> , 2017, 263, e188-e189.	0.4	0
51	Gender differences in acute coronary syndromes: Do they count?. <i>Atherosclerosis</i> , 2017, 263, e193.	0.4	0
52	Plasmatic and phenotypic effects with alirocumab, a PCSK9 inhibitor, in familial hypercholesterolemia treatment (FH). <i>Atherosclerosis</i> , 2017, 263, e246-e247.	0.4	0
53	[OP.3C.01] COMPARISON BETWEEN EUROPEAN SYSTEMATIC CORONARY RISK EVALUATION AND ITALIAN CUORE ALGORITHMS IN ADULT OUTPATIENTS FOLLOWED BY GENERAL PRACTITIONERS AND SPECIALISED CENTRES. <i>Journal of Hypertension</i> , 2017, 35, e30.	0.3	0
54	[OP.6A.06] PREVALENCE AND CLINICAL CHARACTERISTICS OF TRUE MASKED HYPERTENSION COMPARED TO REVERSE AND ISOLATED NOCTURNAL MASKED HYPERTENSION. <i>Journal of Hypertension</i> , 2017, 35, e56.	0.3	0

#	ARTICLE	IF	CITATIONS
55	[PP.01.17] ADDING HYPERTENSION-RELATED MARKERS OF ORGAN DAMAGE TO RISK SCORE MODELS IMPROVES CARDIOVASCULAR RISK ASSESSMENT. <i>Journal of Hypertension</i> , 2017, 35, e97.	0.3	0
56	[PP.04.18] COMPARISON AMONG DIFFERENT ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY. <i>Journal of Hypertension</i> , 2017, 35, e116.	0.3	0
57	Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease. <i>Data in Brief</i> , 2016, 7, 1409-1412.	0.5	7
58	Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. <i>Atherosclerosis</i> , 2016, 246, 214-220.	0.4	29
59	Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations. <i>Vascular Health and Risk Management</i> , 0, Volume 18, 507-515.	1.0	12